# Biomarker and Genetic Predictors of Erenumab Treatment Response

> **NCT04265755** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 1406 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT04265755
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-01-18
- **Target enrollment:** 1406 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265755, "Biomarker and Genetic Predictors of Erenumab Treatment Response". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04265755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*